探究新辅助化疗对胃癌细胞Bcl-2和p53基因表达的影响

胃癌在中国的发病率和死亡率居恶性肿瘤前列,现在胃癌的治疗主要以手术和化疗为主的综合治疗,新辅助化疗是胃癌综合治疗的重要组成部分,通过新辅助化疗能够有效抑制癌细胞增殖、缩小肿瘤体积等优点,从而为手术切除创造条件。本研究用新辅助化疗处理患胃癌的小鼠,并检测了新辅助化疗处理前后胃癌细胞内p53和Bcl-2 (细胞凋亡相关因子)基因在组织内的表达变化情况,以及与对照相比新辅助化疗对肿瘤大小的影响。结果表明,新辅助化疗可以减缓肿瘤的增长,显著上调小鼠胃癌组织内细胞凋亡因子p53的表达,并且显著下调Bcl-2抗凋亡因子的表达,从而有效地抑制胃癌细胞的增殖。这一结果可能为新辅助化疗对胃癌的治疗分子机制提供一些理论支持。

Effect of Neoadjuvant Chemotherapy on Expression of Bcl-2 and p53 Genes in Gastric Cancer Cells

The incidence and mortality of gastric cancer in China are among the highest in malignant tumors. Nowadays, the treatment of gastric cancer is mainly based on surgery and chemotherapy. Neoadjuvant chemotherapy is an important part of comprehensive treatment of gastric cancer. It can effectively inhibit cancer cells proliferation,shrinking tumor volume and other advantages, thus creating conditions for surgical resection. In this study, neoadjuvant chemotherapy was used to treat mice, and the expression of p53 and Bcl-2(apoptosis-related factor) genes in gastric cancer cells was detected before and after the neoadjuvant chemotherapy in this study. We also detested the effect of neoadjuvant chemotherapy on tumor weight of mice. The results showed that neoadjuvant chemotherapy could slow the growth of tumors. The result showed that neoadjuvant chemotherapy significantly up-regulated the expression of apoptosis factor p53 in gastric cancer tissues, and significantly down-regulated the expression of anti-apoptotic factors of Bcl-2, thereby effectively inhibiting the proliferation of gastric cancer cells. This result may provide some theoretical support for the molecular mechanism of neoadjuvant chemotherapy for the treatment of gastric cancer.